In a similar fashion, targeting TrkB, the receptor for BDNF, using the pan-Trk inhibitor entrectinib resulted in decreased tumor growth and increased survival in a diffuse intrinsic pontine glioma model (DIPG) [32]. Here, NTRK2 is linked to diffuse intrinsic pontine glioma.